A multi-stakeholder coalition consisting of representatives from the global patient advocacy and clinical community has formed the International COVID-19 Blood Cancer Coalition (ICBCC) to address the specific impact of the pandemic on immunocompromised blood cancer patients (both acute and chronic), and to recommend solutions and actions to mitigate those risks.
The CLL Advocates Network (CLLAN) is acting as secretariat on behalf of the coalition.
The coalition has prepared a Joint Patient Impact Statement for use in different countries to aid when advocating for the provision of anti-COVID-19 treatment and care for immunocompromised (IC) blood cancer patients.
International COVID-19 Blood Cancer Coalition (ICBCC)
PATIENT IMPACT STATEMENT AND RECOMMENDATIONS
Protecting immunocompromised blood cancer patients during the COVID-19 pandemic
Date of release: 21 February 2022 / last updated: 13 June 2022
The Statement has to date been endorsed by networks and national organisations of the global patient advocacy community as well as renowned medical societies and representatives from the global clinical community
(73 endorsers to date).
The statement is now available for you to use and share!
ICBCC SUCCESS STORIES & ACCESS NEWS
We wish to report on success stories that are reaching us from different countries following the launch of the Patient Impact Statement.
In this section we are listing examples of countries where changes have been observed that can – at least to some degree – be attributed to the coalition´s joint Statement. It´s great to see that the Statement is making impact!
We are also listing Access Updates related to Pre-Exposure Prophylaxis (PrEP) and Post Exposure Prophylaxis or (PEP), and antivirals. These are not directly related to the release of the coalition´s joint Statement.
Thanks for sharing your updates with us by sending an e-mail to firstname.lastname@example.org We will make sure to add your story to the hopefully quickly growing list of inspiring success stories.
The project is split into two phases:
- PHASE I: development of the Joint Patient Impact Statement (completed) and a Lobbying Strategy (completed).
- PHASE II: development of a global campaign, toolkit and materials to help raise awareness of the vulnerability and needs of the wider blood cancer community around COVID-19 prevention and treatment.
Toolbox development to help local / national implementation of the chosen priority actionable objectives agreed on by coalition members. These are: